Proprietary IL-15 Superagonist (N-803) Platform: ImmunityBio possesses N-803 (Anktiva), a first-in-class, superagonist IL-15 cytokine, which has shown promising results in various oncology indications, particularly non-muscle invasive bladder cancer (NMIBC) where it recently secured FDA approval.

Advanced Adenovirus Vector Technology (hAd5): The company utilizes a unique, next-generation human adenovirus type 5 (hAd5) platform designed for enhanced antigen presentation and broad immune activation, serving as a versatile delivery system for cancer vaccines and gene therapies.

Integrated "Killer Cell" Oncology Approach: ImmunityBio pursues a comprehensive "killer cell" approach to cancer treatment, combining activated natural killer (NK) cells, T-cells, and oncolytic viruses, aiming for a multi-pronged attack on tumors and long-term remission.